Modality
Cell Therapy
MOA
BETi
Target
KRASG12D
Pathway
DDR
ADHDProstate CaHemophilia A
Development Pipeline
Preclinical
~Nov 2016
→ ~Feb 2018
Phase 1
May 2018
→ Aug 2031
Phase 1Current
NCT03626421
1,336 pts·Hemophilia A
2018-05→2031-08·Terminated
NCT04482554
1,576 pts·Hemophilia A
2023-08→2031-07·Terminated
2,912 total pts1 indication
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2031-07-055.3y awayInterim· Hemophilia A
2031-08-265.4y awayInterim· Hemophilia A
Trial Timeline
Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q42031Q2Q3Q4
P1
Termina…
P1
Termina…
Catalysts
Interim
2031-07-05 · 5.3y away
Hemophilia A
Interim
2031-08-26 · 5.4y away
Hemophilia A
Terminated|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT03626421 | Phase 1 | Hemophilia A | Terminated | 1336 | Mayo |
| NCT04482554 | Phase 1 | Hemophilia A | Terminated | 1576 | DAS28 |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| JNJ-179 | Johnson & Johnson | Approved | KRASG12C | |
| LLY-1592 | Eli Lilly | NDA/BLA | FGFR | |
| Rilulemzoparlimab | Novartis | Phase 2/3 | KRASG12D | |
| Sovarapivir | AbbVie | Phase 2/3 | IL-13 | |
| BMY-2495 | Bristol-Myers Squibb | Phase 3 | KRASG12D | |
| SNY-2934 | Sanofi | Phase 3 | KRASG12D | |
| Talainavolisib | Novo Nordisk | Preclinical | KRASG12D | |
| BAY-8733 | Bayer | Preclinical | AuroraA | |
| GIL-2037 | Gilead Sciences | Approved | KRASG12D | |
| BII-1564 | Biogen | Phase 2 | PSMA |